Experience of the use of insulin degludec in the treatment of patients with type 1 diabetes mellitus (according to the data of the Moscow segment of the Federal Diabetes Register)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. The basis of modern therapy for type 1 diabetes mellitus (DM1) is the replenishment of the basal and prandial insulin secretion. Introduction into clinical practice of new drugs with a profile of action similar to the physiological insulin action is an extremely important task. The beginning of the use of basal, non-peak long-acting insulin analogs in clinical practice opened the way to ensure adequate glycemic control at night with minimal risk of hypoglycemic states. A new drug of this class, insulin degludec, has demonstrated new possibilities for effectively controlling the glycated hemoglobin (HbA1c) level, reducing glycemic variability and ensuring a low risk of general, nocturnal and severe hypoglycemia compared to other basal insulins. Objective. Evaluation of the glycemic control parameters in patients with type 1 diabetes mellitus receiving insulin degludec. Methods. On the basis of the Moscow segment of the Federal Diabetes register, a sample of patients with type 1 diabetes receiving therapy with insulin deludec since 2016 (n=178) was formed. A statistical analysis of the patient data was conducted: age and sex, the average HbA1c level, the average dose of basal and prandial insulin before insulin degludec administration, and the dynamics of these indicators for 3 years was analyzed. Results. A statistically significant decrease in HbA1с level by 0.6% (from 8.2 to 7.6%) in the period from 2015 to 2016 inclusive (the period of transferring patients to the therapy with insulin degludec) and stable retention of HbA1c at a level of 7.4 % in the next 2 years was revealed. A statistically significant decrease in the average total dose of insulin by 0.04 U/kg (from 0.88 to 0.84 U/kg) due to a decrease in the dose of basal insulin by 0.03 U/kg was observed (p<0.05). At the same time, there was a non-significant tendency to a decrease in the dose of prandial insulin. Conclusion. The transfer of DM1 patients to insulin degludec leads to a statistically significant decrease in HbA1c level. The achieved reduction in HbA1c level persists for at least 2 years. The transfer of DM1 patients to insulin degludec is accompanied by a statistically significant reduction in the dose of basal insulin, while there is no statistically significant change in the dose of prandial insulin.

全文:

受限制的访问

作者简介

Nikolai Demidov

Hospital in Moskovsky town of the Moscow Healthcare Department

Email: nicolay13@mail.ru
PhD, Endocrinologist Moscow, Russia

O. Mishra

City Outpatient Clinic № 5 of the Moscow Healthcare Department

Moscow, Russia

M. Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

Moscow, Russia

参考

  1. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г Сахарный диабет. 2018;21(3):144-59. doi: 10.14341/DM9686.
  2. Демидов Н.А., Мишра О.А., Анциферов М.Б. Сахарный диабет 1 типа в Москве - 2018 г (по данным Московского сегмента Федерального регистра сахарного диабета). Фарматека. 2018;11:74-8. Doi: https://dx.doi. org/10.18565/pharmateca.2018.11.74-8.
  3. Heise T., Hermanski L., Nosek L., et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabet Obes Metab. 2012;14:859-64.
  4. Heise T., Hovelmann U., Nosek L., et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract). Diabetol. 2011; 54:5425.
  5. Kurtzhals P., Heise T., Strauss H.M., et al. Multihexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract). Diabetol. 2011;54:5426.
  6. Heise T., Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabet Obes Metab. 2017;19:3-12
  7. Инструкция по применению препарата Тресиба® ФлексТач®. Доступно на: http://grls.rosminzdrav. ru [Instructions for use of the drug Tresiba® FlexTach®. Available at: http://grls.rosminzdrav.ru (In Russ.)].
  8. Ratner R.E., Gough S.C., Mathieu C., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabet Obes Metab. 2013;15:175-84.
  9. Marso S.P., McGuire D.K., Zinman B., et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med. 2017;377:723-32.
  10. Siegmund T., Tentolouris N., Knudsen S.T., et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabet Obes Metab. 2018;20:689-97. doi: 10.1111/dom.13149.
  11. Демидов Н.А., Котешкова О.М., Пашкова Е.Ю., Мишра О.А. Использование инсулинового дозатора Акку-чек Спирит Комбо в терапии больных сахарным диабетом 1-го типа. Consilium Medicum. 2018;20(12):128-34. doi: 10.26442/20751753.2018.12.180140.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2019